astragaloside a has been researched along with tetradecanoylphorbol acetate in 1 studies
| Studies (astragaloside a) | Trials (astragaloside a) | Recent Studies (post-2010) (astragaloside a) | Studies (tetradecanoylphorbol acetate) | Trials (tetradecanoylphorbol acetate) | Recent Studies (post-2010) (tetradecanoylphorbol acetate) |
|---|---|---|---|---|---|
| 675 | 5 | 573 | 31,050 | 61 | 2,217 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Geng, Y; He, C; Li, L; Li, Y; Liang, X; Ma, Y; Shu, G; Song, X; Ye, G; Yin, L; Yin, Z; Yue, G; Zhang, R; Zhao, Y; Zou, Y | 1 |
1 other study(ies) available for astragaloside a and tetradecanoylphorbol acetate
| Article | Year |
|---|---|
Astragaloside IV inhibits PMA-induced EPCR shedding through MAPKs and PKC pathway.
Topics: Antigens, CD; Endothelial Protein C Receptor; Extracellular Signal-Regulated MAP Kinases; Human Umbilical Vein Endothelial Cells; Humans; MAP Kinase Signaling System; Protein Kinase C; Receptors, Cell Surface; Saponins; Tetradecanoylphorbol Acetate; Triterpenes | 2017 |